Search research articles
Contact Us
Filters
Showing results (331-340 of 354) with videos related to
Page
of 36
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
Margarita Majem, Jonathan W Goldman, Thomas John, et al.
Journal for Immunotherapy of Cancer
|
February 12, 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
David P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
The New England Journal of Medicine
|
September 21, 2020
Osimertinib in Resected <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu, Masahiro Tsuboi, Jie He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
George D Demetri, Filippo De Braud, Alexander Drilon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2023
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
Roy S Herbst, Yi-Long Wu, Thomas John, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 12, 2025
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer
Stephanie P L Saw, Wen-Zhao Zhong, Rui Fu, et al.
The Lancet. Oncology
|
January 21, 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 25, 2018
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma
Yannis Metaxas, Gareth Rivalland, Laetitia A Mauti, et al.
The New England Journal of Medicine
|
May 29, 2026
First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion Mutations
Caicun Zhou, Laurent Greillier, Geoffrey Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer
Hossein Borghaei, David Balli, Luis G Paz-Ares, et al.
Page
of 36
Search research articles
Search
Showing results (331-340 of 354) with videos related to
Sort By:
Page
of 36
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
Margarita Majem, Jonathan W Goldman, Thomas John, et al.
Journal for Immunotherapy of Cancer
|
February 12, 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
David P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
The New England Journal of Medicine
|
September 21, 2020
Osimertinib in Resected <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu, Masahiro Tsuboi, Jie He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
George D Demetri, Filippo De Braud, Alexander Drilon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2023
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
Roy S Herbst, Yi-Long Wu, Thomas John, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 12, 2025
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer
Stephanie P L Saw, Wen-Zhao Zhong, Rui Fu, et al.
The Lancet. Oncology
|
January 21, 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 25, 2018
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma
Yannis Metaxas, Gareth Rivalland, Laetitia A Mauti, et al.
The New England Journal of Medicine
|
May 29, 2026
First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion Mutations
Caicun Zhou, Laurent Greillier, Geoffrey Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer
Hossein Borghaei, David Balli, Luis G Paz-Ares, et al.
Page
of 36